P. Grivas, A. Mortazavi, J. Picus
Dec 20, 2018
Citations
0
Influential Citations
34
Citations
Journal
Cancer
Abstract
The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single‐arm, open‐label phase 2 study.